A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs SY 1365 (Primary)
  • Indications Advanced breast cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Syros Pharmaceuticals
  • Most Recent Events

    • 09 Aug 2017 According to a Syros Pharmaceuticals media release, compnay expects to report preliminary clinical data in 2018.
    • 15 May 2017 According to a Syros Pharmaceuticals media release, the first patient has been dosed in this trial. Anthony W. Tolcher is an investigator of this trial.
    • 02 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top